A Phase 3 interventional study of CagriSema (Cagrilintide B and Semaglutide I) and Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Recruiting at 58 sites in 10 countries. Open to participants aged 10 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 4 of them phase 3. cagrilintide · Diabetes Mellitus, Type 2.
Among the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, this one is the 14th largest by planned enrollment, is one of 4 that started in 2026, is one of 10 in phase 3, and was the 12th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 10 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cagrilintide is the treatment under test here. Read study by study →
15 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 80 is close to the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 274 across the 15 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 1 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 291st largest by planned enrollment of the 428 interventional ones that give a count, is one of 23 that started in 2026, is one of 187 in phase 3, reaches primary completion later than 26 of the 28 other live ones, and was the 622nd registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
2 of the studies testing cagrilintide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, from their registry updates:
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their blood sugar and body weight. The study has 2 parts: in the first part participant will get either CagriSema or placebo, and in the second part participant will get CagriSema. In the first part, which treatment participant gets is decided by chance and second part is open label and all participants will get CagriSema during this part. The study will last for about 1 year and 3 months.
Key Inclusion Criteria:
of parent(s) or legally acceptable representative (LAR) of participant and child assent, as age-appropriate, obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
Treated with diet and exercise counselling alone or with a stable daily dose(a), in addition to diet and exercise counselling, of any of the following antidiabetic drugs or combination regimens:
Body weight ≥ 45 kg and ≥ 85th percentile(b). BMI will be calculated in the electronic case report form based on height and body weight at screening.
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive CagriSema (Cagrilintide B + Semaglutide I) subcutaneously once weekly for 26 weeks in Part 1.
Drug: CagriSema (Cagrilintide B and Semaglutide I)
Participants will receive placebo matched to CagriSema (Cagrilintide B + Semaglutide I) subcutaneously once weekly for 26 weeks in Part 1.
Drug: Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Participants who received placebo in Part 1 will receive CagriSema (Cagrilintide B + Semaglutide I) subcutaneously once weekly for 26 weeks in Part 2.
Drug: CagriSema (Cagrilintide B and Semaglutide I)
Drug page: Cagrilintide
Cagrilintide B and Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
Placebo matched to Cagrilintide B and Placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
This study also gives Semaglutide. No intervention listed here names it: that was found by reading the record.
Change in glycated haemoglobin (HbA1c)
Measured as percentage (%) of HbA1c.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Relative change in body mass index (BMI)
Measured as percentage.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Number of participants with achievement of HbA1c target values of less than (<) 7.0% (< 53 millimole per mole [mmol/mol])
Measured as count of participants.
Time frame: At end of double-blinded treatment (week 26)
Number of participants with achievement of HbA1c target values of less than or equal to (≤) 6.5% (≤48 mmol/mol)
Measured as count of participants.
Time frame: At end of double-blinded treatment (week 26)
Change in time in range (TIR) 3.9-10.0 millimole per liter (mmol/L) (70-180 milligram per deciliter (mg/dL) measured using continuous glucose monitoring (CGM)
Measured as percentage of time.
Time frame: From baseline (collected during week -3, -2 and -1) to end-of-double-blinded treatment (collected during week 22, 23, 24, and 25)
Change in time in tight target range (TITR) 3.9-7.8 mmol/L (70-140 mg/dL) measured using CGM
Measured as percentage of time.
Time frame: From baseline (collected during week -3, -2 and -1) to end-of-double-blinded treatment (collected during week 22, 23, 24, and 25)
Change in time above range (TAR) greater than (>) 10.0 mmol/L (> 180 mg/dL) measured using CGM
Measured as percentage of time.
Time frame: From baseline (collected during week -3, -2 and -1) to end-of-double-blinded treatment (collected during week 22, 23, 24, and 25)
Change in TAR greater than (>) 13.9 mmol/L (> 250 mg/dL) measured using CGM
Measured as percentage of time.
Time frame: From baseline (collected during week -3, -2 and -1) to end-of-double-blinded treatment (collected during week 22, 23, 24, and 25)
Change in mean sensor glucose concentration measured by CGM
Measured as mmol/L.
Time frame: From baseline (collected during week -3, -2 and -1) to end-of- double-blinded treatment (collected during week 22, 23, 24, and 25)
CGM: Within-day glycaemic variability (% coefficient of variation)
Measured as percentage.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Number of participants with incidence of glycaemic rescue therapy
Measured as count of participants
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Change in fasting plasma glucose
Measured as mmol/L.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Number of participants with achievement of greater than or equal to (≥) 5% BMI reduction
Measured as count of participants.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Number of participants with achievement of ≥ 10% BMI reduction
Measured as count of participants.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Number of participants with achievement of ≥ 15% BMI reduction
Measured as count of participants.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Relative change in body weight
Measured as percentage of body weight.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Change in BMI standard deviation score (SDS)
Measured as score on scale.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Change in waist circumference
Measured as centimetre (cm).
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Change in waist-to-height ratio
Measured as ratio.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Change in systolic blood pressure
Measured as millimetre of mercury (mmHg).
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Change in diastolic blood pressure
Measured as mmHg.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Ratio to baseline in lipid: total cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Ratio to baseline in lipid: high density lipoprotein (HDL) cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Ratio to baseline in lipid: low density lipoprotein (LDL) cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Ratio to baseline in lipid: very low density lipoprotein (VLDL) cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Ratio to baseline in lipid: triglycerides
Measured as ratio.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Ratio to baseline in lipid: Non-HDL cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Change in alanine aminotransferase (ALT)
Measured as units per liter (U/L).
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26) and end of extension phase treatment (week 52)
Apparent clearance (CL/F) of cagrilintide and semaglutide
Measured as liter per hour (L/h).
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Average concentration (Cavg) of cagrilintide and semaglutide at steady state
Measured as nanomole per liter (nmol/L).
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Change in insulin dose
Measured as units (U).
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Number of participants with achievement of sustained insulin dose = 0 U
Measured as count of participants.
Time frame: At end of double-blinded treatment (week 26)
Ratio to baseline in urine albumin-creatinine ratio (UACR)
Measured as ratio.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Ratio to baseline in biomarker related to glucose metabolism: fasting C-peptide
Measured as ratio.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Ratio to baseline in biomarker related to glucose metabolism: fasting insulin
Measured as ratio.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Ratio to baseline in biomarker related to glucose metabolism: fasting proinsulin
Measured as ratio.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Ratio to baseline in biomarker related to glucose metabolism: fasting glucagon
Measured as ratio.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Ratio to baseline in high sensitivity C-reactive protein (hsCRP)
Measured as ratio.
Time frame: From baseline (week 0) to end of double- blinded treatment (week 26)
Ratio to baseline in free fatty acids
Measured as ratio.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Ratio to baseline in leptin
Measured as ratio.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Ratio to baseline in soluble leptin receptor
Measured as ratio.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Ratio to baseline in leptin to soluble leptin receptor ratio
Measured as ratio.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Change in aspartate aminotransferase (AST)
Measured as U/L.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26) and end of extension phase treatment (week 52)
Change in alkaline phosphatase (ALP)
Measured as U/L.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26) and end of extension phase treatment (week 52)
Change in bilirubin
Measured as U/L.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26) and end of extension phase treatment (week 52)
Change in HbA1c
Measured as percentage of HbA1c.
Time frame: From baseline (week 0) to end of extension phase treatment (week 52)
Number of clinically significant hypoglycaemic episodes (level 2) (< 3.0 mmol/L (54 mg/dL) confirmed by blood glucose [BG] meter)
Measured as count of episodes.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Number of severe hypoglycaemic episodes (level 3) - severe hypoglycaemia being defined as severe cognitive impairment requiring assistance by another person to administer carbohydrates, glucagon, or intravenous glucose
Measured as count of episodes.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Change in percentage of time below range (TBR) < 3.0 mmol/L (< 54 mg/dL) measured using CGM
Measured as percentage of time.
Time frame: At end of double-blinded treatment (collected during week 22, 23, 24, and 25)
Change in TBR < 3.9 mmol/L (< 70 mg/dL) measured using CGM
Measured as percentage of time.
Time frame: At end of double-blinded treatment (collected during week 22, 23, 24, and 25)
Number of treatment-emergent adverse events
Measured as count of events.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Height velocity
Measured as cm/year.
Time frame: At end of double-blinded treatment (week 26)
Change in height SDS
Measured as score on scale.
Time frame: From baseline (week 0) to end of double-blinded treatment (week 26)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Sep 2029, 37 months after the start.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 37 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cagrilintide